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artin S. Maron, MD, James E. Udelson, MD
oston, Massachusetts
entricular remodeling, first described in animal models of left ventricular (LV) stress and injury, occurs
rogressively in untreated patients after large myocardial infarction and in those with dilated forms of
ardiomyopathy. The gross pathologic changes of increased LV volume and perturbation in the normal
lliptical LV chamber configuration is driven, on a histologic level, bymyocyte hypertrophy and apoptosis
nd by increased interstitial collagen. Each of the techniques used for tracking this process—echocardi-
graphy, radionuclide ventriculography, and cardiac magnetic resonance—carries advantages and dis-
dvantages. Numerous investigationshavedemonstrated the valueof LV volumemeasurement at a single
ime-point and over time in predicting clinical outcomes in patients with heart failure and in those after
yocardial infarction. The structural pattern of LV remodeling and evidence of scarring on cardiac mag-
etic resonance have additional prognostic value. Beyond the impact of abnormal cardiac structure on
ardiovascular events, the relationship between LV remodeling and clinical outcomes is likely linked
hrough common local and systemic factors driving vascular as well as myocardial pathology. As demon-
trated by a recent meta-analysis of heart failure trials, LV volume stands out among surrogate markers as
trongly correlating with the impact of a particular drug or device therapy on patient survival. These
ndings substantiate the importance of ventricular remodeling as central in the pathophysiology of
dvancing heart failure and support the role of measures of LV remodeling in the clinical investigation of
ovel heart failure treatments. (J AmColl Cardiol Img 2011;4:98–108) © 2011 by the American College of
ardiology Foundationa
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he term ventricular remodeling refers to alter-
tion in ventricular architecture, with associ-
ted increased volume and altered chamber
onfiguration, driven on a histologic level by a
ombination of pathologic myocyte hypertro-
hy, myocyte apoptosis, myofibroblast prolifer-
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riginally described after myocardial infarction
MI), ventricular remodeling develops in re-
ponse to a variety of forms of myocardial
njury and increased wall stress (4,5).
Early work by Pfeffer and Braunwald (6) in a
odent MI model showed that a greater degree
f myocardial injury was associated with a
reater degree of chamber remodeling over
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99ime. Since that time, multiple studies have sub-
tantiated the relationship between infarct size and
he extent of left ventricular (LV) remodeling
3,7,8). Solomon et al. (9) showed that patients
ith larger MIs, as evidenced by greater elevations
n serum creatine kinase concentrations, manifest
reater 90-day increases in LV end-diastolic vol-
me (EDV) and greater reductions in left ventric-
lar ejection fraction (LVEF) (Fig. 1).
The initial post-MI phase of LV remodeling
esults from fibrotic repair of the necrotic area with
car formation, elongation, and thinning of the
nfarcted zone (Fig. 2). LV volumes increase, a
esponse that is sometimes considered adaptive,
ssociated with stroke volume augmentation and
aintenance of normal cardiac output (10). How-
ver, beyond this early stage, the remodeling pro-
ess is driven predominantly by hypertrophic myo-
yte elongation in the noninfarcted zone, resulting
n increased wall mass, chamber enlargement, and a
hift from an elliptical to a more spherical chamber
onfiguration (3,11–13). These changes, together
ith a decline in performance of the pathologically
ypertrophied myocyte and interstitial fibrosis
ithin the noninfarcted zone, result in progressive
ecline in ventricular performance. Left unchecked,
V hypertrophy, dilation, and contractile dysfunc-
ion appear to advance indefinitely, regardless of the
nitial inciting cause, as evidenced by progressive
ncreases in LV volumes (12,14,15).
Pathologic LV remodeling is closely linked to
ctivation of a series of neuroendocrine, paracrine,
nd autocrine factors, which are up-regulated after
yocardial injury and in the setting of increased LV
all stress and hemodynamic derangement. Con-
ributing factors include the renin-angiotensin-
ldosterone axis, the adrenergic nervous system,
ncreased oxidative stress, proinflammatory cyto-
ines, and endothelin. Renin-angiotensin system
nhibition (14–18) and beta-adrenergic blockade
19–23) have each been shown to markedly atten-
ate or reverse LV remodeling in patients with
eart failure and LV dilation, although aldosterone
lockade has yielded mixed results (24,25), and
ndings with antagonists of endothelin (26) and
asopressin (27) have been disappointing.
With continued application of imaging tech-
iques within populations of patients with MI
nd/or heart failure, there has been increased un-
erstanding of the various macroscopic patterns of
V remodeling and their relationship to underlying
tiology and prognosis. Verma et al. (28), examin-
ng patients with heart failure and/or LVEF 35% sfter MI, in the VALIANT (VALsartan In Acute
yocardial iNfarcTion) echocardiographic study,
efined 3 patterns of LV remodeling based on
easurement of the LV mass index (LVMi) and
elative wall thickness (RWT): concentric remod-
ling (normal LV mass index LVMi and increased
WT), eccentric hypertrophy (increased LVMi and
ormal RWT), concentric hypertrophy (increased
VMi and increased RWT) (Fig. 3) (28). Each of
hese patterns was associated with a higher risk of
ubsequent cardiovascular events than that of nor-
al LV morphology, with each of these 3 patterns
arrying progressively worse prognosis (see the “Re-
ationship between LV remodeling and prognosis in
atients with heart failure and decreased LVEF”
ection).
echniques for Assessing Ventricular
emodeling
VEF, the most common metric of car-
iac performance in clinical practice, is
nfluenced by the degree of LV remodel-
ng more than by any other factor (29).
ther, more precise metrics of remodel-
ng, such as LV volumes and mass, have
eceived greater focus in clinical trials than
n clinical practice (30), yet these measure-
ents relate more closely to prognosis and
o the impact of therapy than does LVEF.
or example, White et al. (31) demon-
trated that within groups with various
egrees of post-MI LV dysfunction de-
ned by LVEF, analysis of LV end-
ystolic volume (ESV) further risk-
tratified patients, suggesting that it is a
ore powerful metric for that purpose.
t present, echocardiography remains the pre-
ominant clinically applicable noninvasive test of
hoice, based on broader availability, whereas
lternative modalities, such as radionuclide imag-
ng and cardiac magnetic resonance (CMR), also
lay an important role, with each modality offer-
ng advantages and disadvantages.
wo-dimensional (2D) and 3-dimensional (3D)
chocardiography. 2D echocardiography is a widely
vailable and well-established means of assessing LV
emodeling. This technique can be performed in
early all patients, including those who are critically ill,
nd is not associated with any radiation exposure.
owever, estimates of LV volumes derived from 2D
mages are subject to variability and error imposed by
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100ying the endocardial border, geometric assumptions
nderlying the volumetric calculations, and beat-to-
eat variation in LV volume and function.
Kober et al. (32) demonstrated the accuracy of
chocardiographic LV volumes estimates, using the
impson method when compared with in vitro
anine measurements. A number of studies have
emonstrated the superior reproducibility of 2D
chocardiography over M mode for measuring LV
ass in normal subjects (33,34) and those with
bnormal LV geometry (35). Subsequently, har-
onic imaging (36) and contrast echocardiography
37) have improved 2D echocardiographic image
uality.
More recently, real-time 3D echocardiography
as emerged as a clinically feasible method for
uantifying ventricular volume and mass. 3D echo-
ardiographic quantification of ventricular volumes
nd ejection fraction can be performed rapidly and
voids the geometric assumptions and problems of
mage plane position that are associated with 2D
chocardiography. 3D echocardiography has supe-
ior accuracy and reproducibility for evaluation of
entricular chambers compared with 2D echocardi-
graphy, and several studies have observed that 3D
chocardiographic assessments of ventricular vol-
mes, mass, and ejection fraction correlate favorably
ith CMR (38–42).
adionuclide ventriculography. Equilibrium-gated
adionuclide ventriculography (RVG) has been used
ince the 1970s to assess right ventricular and LV
unction, with studies of ventricular volumes following
Subsequent Remodeling
ocardial infarctions (MI), as reﬂected by higher serum creatine kinase
r 90-day increases in left ventricular end diastolic volume (LVEDV)
ler MI. Adapted, with permission, from Solomon et al. (57).oon thereafter. Because ventricular volumes are de- aermined by changes in radionuclide counts, the RVG
echnique is independent of geometric assumptions
nd does not rely on operator-defined analysis of
egional changes in wall motion or thickening
hroughout the cardiac cycle (30,43). This factor is
specially advantageous over other imaging techniques
n patients with ischemic cardiomyopathy, multiple
all motion abnormalities, and altered LV geometry.
ecause the radionuclide-based volumetric estimate
ntegrates information from multiple cardiac cycles,
he technique is not subject to error from individual
eat-to-beat variation. Gating methodologies are de-
igned to manage moderate cycle-length variability,
lthough extreme variability, as when ventricular re-
ponse to atrial fibrillation is excessively irregular, may
ntroduce error into volumetric and functional
stimates.
Multiple studies have demonstrated adequate
eproducibility and low intraobserver and interob-
erver variability of RVG in estimating LV volumes
n both normal subjects and those with heart
isease. Studies comparing RVG with both contrast
entriculography (44,45) and visual estimation by
D echocardiography (46) found that RVG is
omparable to these 2 methods in estimating LVEF
nd has higher reproducibility.
Like any imaging modality, a high-quality, re-
roducible study is dependent on operator expertise
n acquisition and analysis. Although LV volumes
ay not be routinely reported in many cardiac
uclear medicine laboratories, laboratories with
ualified physicians and technologists can be
rained to acquire high-quality data, and central
ata analysis will optimize accuracy and reproduc-
bility of volumetric estimates for clinical trial
urposes.
MR. CMR is a 3D imaging technique producing
mages with high spatial and temporal resolution.
he generation of thin, short-axis imaging slices
ith full ventricular coverage results in truly tomo-
raphic imaging without the limitation of geo-
etric assumptions associated with 2D non-
omographic imaging techniques. In addition,
ontemporary imaging sequences generate sharp
ontrast between the bright blood pool and dark
yocardium, which results in accurate measure-
ents of volume, mass, and wall thickness. A
umber of investigations have demonstrated strong
orrelations for LVEFs and volumes measured by
MR versus contrast angiography or echocardiog-
aphy (47,48). CMR is now considered the refer-
nce for noninvasive measurements of functionalFigure 1. MI Size and
Patients with larger my
(CK) levels, show greatend volumetric parameters. In addition, the supe-
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101ior reproducibility of these measurements with
MR facilitates application of CMR as a research
ool for clinical investigation. For example, the
ample size needed to demonstrate a given change
n volume or mass with statistical confidence is
ubstantially reduced with CMR compared with
D echocardiography, a factor that may offset the
ncreased cost of CMR by virtue of the savings from
tudying fewer patients per trial (49).
Beyond geometric measurements, contrast-
nhanced CMR, with assessment of late gadolin-
um enhancement (LGE), has demonstrated the
bility to predict patient risk of adverse remodeling
ost-MI (50–52). Due to the high spatial resolu-
ion, LGE, a marker of myocardial scarring, can
dentify acute and chronic MI with high accuracy
nd reproducibility (53). Areas of LGE can be
lanimetered, and the amount quantified and ex-
ressed as a percentage of the total LV mass or a
ercentage of the LV wall segment involved (50).
his technique can also demonstrate microvascular
bstruction, as evidenced by a central dark zone,
urrounded by bright enhancement of the infarcted
ore (54), a finding that marks a greater risk of
dverse LV remodeling post-MI.
elationship Between LV Remodeling
nd Prognosis in Patients With
eart Failure and Decreased LVEF
elationship between clinical outcomes and cross-
ectional LV measurements. In 1987, White et al.
31) observed that LVEF measured 1 to 2 months
Figure 2. Ventricular Remodeling: Gross and Microscopic Archit
Schematic representation of post-myocardial infarction (post-MI) lef
and elongation of the ﬁbrous scar within the infarcted zone. Subse
more spherical conﬁguration, is driven principally by diffuse myocy
increases in interstitial collagen. Figure illustration by Craig Skaggs.fter thrombolytic therapy for MI was a powerfulredictor of prognosis, with LV ESV index (ESVi)
roviding additional predictive value. In a similar
opulation, Migrino et al. (55) demonstrated a
ontinuous relationship between ESVi and both
ortality and the development of heart failure
ymptoms. In a population with symptomatic heart
ailure and decreased LVEF, Lee et al. (56) found
hat LV end-diastolic dimension index, measured
ith M-mode echocardiography, was an indepen-
ent predictor of survival. In an echocardiographic
re
ntricular remodeling. The early phase is characterized by thinning
t left ventricular dilation, with transition from an elliptical to a
ypertrophy associated with increased apoptosis (not shown) and
Figure 3. Patterns of Remodeling
The echocardiographic substudy of the VALIANT (VALsartan In Acut
iNfarcTion) trial deﬁned 3 patterns of left ventricular (LV) remodelin
heart failure and/or LV ejection fraction 35%, based on measurem
lar mass index (LVMi) and relative wall thickness (RWT): concentric r
LVMi and increased RWT), eccentric hypertrophy (increased LVMi an
centric hypertrophy (increased LVMi and increased RWT). Reprintedectu
t ve
quen
te he myocardial
g in patients with
ent of left ventricu-
emodeling (normal
d normal RWT), con-
, with permission,from Verma et al. (28).
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102ubstudy of the VALIANT (Valsartan in Acute
yocardial Infarction) study, Solomon et al. (57)
emonstrated that baseline LVEF, EDV, and ESV
ere each independent predictors of the primary
ombined end point of death or heart failure hos-
italization (Fig. 4).
Recently, investigators have begun to clarify the dif-
erential prognostic implication of different patterns of
V remodeling. In the VALIANT echocardiographic
tudy, Verma et al. (28) found that, compared with
atients without evidence of LV remodeling, patients
ith any of the patterns of LV remodeling post-MI had
greater risk of the composite of cardiovascular death,
I, heart failure, stroke, or resuscitated cardiac arrest. In
ddition, the patterns of concentric remodeling, eccentric
ypertrophy, and concentric hypertrophy were associated
ith a progressively increased risk of the composite, with
ach of the individual outcome components following a
attern of risk similar to that of the overall composite
Fig. 5). Thus, although LV volumes remain powerful
ndicators of cardiovascular prognosis, additional infor-
ation is contained within the specific pattern of LV
emodeling.
These findings point to additional hypotheses related
o the nature of the linkage between LV remodeling and
ardiovascular events (29). First, the greater adverse
mplication of concentric hypertrophy suggests that an-
ecedent hypertension of sufficient severity and duration
o discernably affect LV structure carries an incremental
isk in a patient with subsequent MI. Second, the
imilarity of risk patterns for subsequent MI and stroke,
Figure 4. Ventricular Measurements and Prognosis
Relationship between echocardiographic parameters, ejection fracti
bined outcome of death or hospitalization for heart failure (HF) aft
et al. (57).ompared with that of heart failure and the overall
omposite end point, suggests that the mechanisms
esponsible for adverse outcomes are not simply operat-
ng through cardiac dysfunction and clinical heart failure.
ather, it is likely that LV remodeling represents a more
lobal biomarker of systemic effects, such as that of
ypertension and neurohormonal activation, on the en-
ire cardiovascular system, with a likely association be-
ween LV remodeling and vascular changes responsible
or coronary and cerebrovascular events.
The extent of LGE by CMR may also represent
n important prognostic indicator. The number of
V segments with transmural (i.e., LGE occupying
75% of the LV segment) involvement post-MI is
redictive of the extent of subsequent LV remod-
ling, as evidenced by increased LV volumes and
ecreased LVEF, independent of the magnitude of
roponin increase (58). The extent of LGE also
redicts the likelihood of functional recovery after
ither coronary revascularization or medical ther-
py. Those LV segments without LGE have ap-
roximately an 80% chance for improvement in
unction post-revascularization (52). Similarly, in
atients with heart failure and decreased LVEF,
ystolic performance improved in more than half of
V segments without LGE, but in only rare seg-
ents with transmural LGE after 6 months of
eta-blocker therapy (59). CMR evidence of mi-
rovascular obstruction post-MI predicts a greater
ikelihood of thinning and lack of functional recov-
ry in a particular myocardial segment and a greater
end-diastolic volume, and infarct segment length, and the com-
yocardial infarction. Reprinted, with permission, from Solomonon,
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103verall likelihood of future adverse cardiovascular
vents (60).
Although more work is needed in this area, it is
ikely that the combination of LV geometric indi-
ators, such as volumes and overall patterns of
emodeling, along with myocardial characteristics,
uch as LGE and microvascular obstruction, will
ogether form a powerful constellation of findings
redicting subsequent clinical outcomes.
elationship between clinical outcomes and longitudinal
V measurements. A number of studies have sup-
orted the value of serial changes in parameters of
V remodeling for predicting clinical outcomes in
atients with LV dilation and/or decreased LVEF.
ata from the echocardiographic substudy of the
AVE (Studies of Ventricular Enlargement) trial
emonstrated that longitudinal changes in LV area
1 year after MI significantly correlated with
ubsequent long-term rates of cardiovascular events,
ndependent of randomization to either captopril or
lacebo (Fig. 6) (61). Similarly, echocardiographic
ata from the Val-HeFT (Valsartan Heart Failure
rial) in 5,010 patients with heart failure and both
VEF 40% and LV end-diastolic dimension
ndex 2.9 cm/m2, showed that both baseline LV
nd-diastolic dimension index and LVEF and
hanges in these parameters over time were inde-
Figure 5. Remodeling Patterns and Cardiovascular Events
Compared with patients without evidence of left ventricular (LV) re
myocardial infarction (MI) had a greater risk of the composite of ca
cardiac arrest. In addition, the patterns of concentric remodeling, ec
with a progressively increased risk of the composite end point, with
similar to that of the overall composite. SD  sudden death. Reprinendent predictors of patient outcome (62).elationship Between an Intervention’s Effect
n Remodeling and its Effect on Clinical Outcomes
n Patients with Heart Failure and Decreased LVEF
eyond mere prognostication, measures of LV
emodeling have been used extensively to gauge the
ffect of drug and device interventions on cardiac
tructure and function. In a radionuclide ventricular
eling, patients with any of the patterns of LV remodeling post-
vascular (CV) death, MI, heart failure (HF), stroke, or resuscitated
tric hypertrophy, and concentric hypertrophy were associated
ch of the individual outcome components following a risk pattern
, with permission, from Verma et al. (28).
Figure 6. Longitudinal Ventricular Dilation and Prognosis
Changes in left ventricular (LV) area at end-systole and end-diastole
1 year in patients after myocardial infarction with baseline left ventric
function, from the SAVE (Studies of Ventricular Enlargement) trial, c
in patients who sustained versus those who did not sustain adverse
vascular (CV) events. Patients experiencing events had a signiﬁcantl
increase in areas (i.e., more adverse remodeling) compared with thomod
rdio
cen
eaover
ular dys-
ompared
cardio-
y greater
se whohad no events. Adapted, with permission, from St. John Sutton et al. (61).
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104unction substudy of the SOLVD (Studies of Left
entricular Dysfunction) trial, we demonstrated
ifferences in serial measures of LV volumes for
atients randomized to the angiotensin-converting
nzyme inhibitor enalapril versus those randomized
o placebo, which paralleled the enalapril effect on
ll-cause mortality and on heart failure hospitalization.
e observed that enalapril prevented or reversed the
rogressive remodeling process seen in placebo-group
atients with an LVEF35%, either with (treatment
rial) (14) or without (prevention trial) (15) heart
ailure symptoms (Fig. 7).
Numerous studies have shown favorable effects on
arameters of LV remodeling for drugs that improve
linical outcomes in patients with decreased LVEF
nd LV dilation, notably angiotensin-converting en-
yme inhibitors, beta-blockers, and angiotensin recep-
or blockers (14,15,18,57,63–69). Conversely, agents
ith neutral or adverse effects on remodeling, relative
o a comparator, have often been found to be associ-
ted with neutral or adverse effects on clinical out-
omes. Examples include omapatrilat (70,71) and
bopamine (72,73). In a head-to-head comparison of
he angiotensin-converting enzyme inhibitor capto-
ril, 150 mg daily, with the angiotensin receptor
locker losartan, 50 mg daily, we found a trend
avoring captopril in the 1-year change in LV volumes
18), an effect that presaged the mortality findings in
LITE (Early Versus Late Intervention Trial With
stradiol) II (74). Yu et al. (75) showed that a
Figure 7. Angiotensin Converting Enzyme Inhibitor Effects on V
Changes in left ventricular end-diastolic volume over time in asymp
decreased left ventricular ejection fraction while randomized to pla
function) trials. During long-term follow-up, patients randomized to
ular end-diastolic volume, whereas those randomized to enalapril s
withdrawal of placebo or enalapril. Adapted, with permission, from Konecrease in LV ESV of10% after cardiac resynchro-
ization therapy predicted decreased long-term mor-
ality and heart failure events, whereas symptomatic
mprovement did not. More recently, in separate
rials, the vasopressin V2 receptor antagonist tolvaptan
as shown to have a neutral effect on both ventricular
emodeling and long-term clinical outcomes (27,76).
n contrast, in 2001, Bozkurt et al. (77), examining
-month changes in LVEF, EDV, and ESV, showed
dose-dependent, placebo-controlled reverse remod-
ling effect over 3 months with etanercept, an inhib-
tor of tumor necrosis factor-alpha. Three years later,
much larger, long-term study failed to show any
ong-term clinical outcome benefit (78). Conversely,
e were unable to demonstrate a benefit of the
ldosterone receptor blocker eplerenone on LV re-
odeling in a group of patients with class II and III
eart failure and decreased LVEF (25), despite the
avorable impact that this class of agent has exerted in
elect patient populations with heart failure and de-
reased LVEF (79,80). Nevertheless, it appears that in
ost, but not all, cases there is concordance between
n intervention’s effect on LV remodeling and heart
ailure–related clinical outcomes for patients with
educed LVEF, either post-MI or with chronic heart
ailure.
Recently, we performed a meta-analysis examining
he relationship between drug- or device-induced
hanges in parameters of LV remodeling and the
ffects of the same interventions on mortality in
ricular Volumes
atic (Prevention) and symptomatic (Treatment) patients with
o or enalapril, from the SOLVD (Studies of Left Ventricular Dys-
cebo demonstrate evidence of progressive increase in left ventric-
ed reductions in left ventricular volume. wd  restudy afterent
tom
ceb
pla
how
stam et al. (14,15).
p
W
f
e
t
r
a
t
v
p
W
t
s
d
(
0
c
b
n
p
t
c
a
c
r
i
a
c
t
a
l
t
e
d
o
m
m
b
c
c
s
d
a
C
T
l
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 1 , 2 0 1 1
J A N U A R Y 2 0 1 1 : 9 8 – 1 0 8
Kramer et al.
Left Ventricular Remodeling in Heart Failure
105atients with heart failure and decreased LVEF (81).
e classified 25 drug or device interventions as having
avorable, neutral, or unfavorable effects on survival,
stimating the odds ratio for death for each interven-
ion compared with placebo based on large-scale,
andomized, controlled outcome trials. We then ex-
mined the correlation between these odds ratios and
he placebo-corrected change from baseline in LV
olumes observed in 88 individual remodeling studies
erformed with each of these interventions (Fig. 8).
e found significant correlations between longer
erm trial-level therapeutic effects on mortality and
hort-term trial-level therapeutic effects of a drug or
evice on LVEF (r  0.51, p  0.001), EDV
r  0.44, p  0.002), and ESV (r  0.48, p 
.002). Furthermore, these drug-/device-induced
hanges in ventricular remodeling reflect the proba-
ility of a categorical mortality outcome (favorable,
eutral, or adverse) for those therapies. These findings
rovide the best support available linking interven-
ional effects on the process of LV remodeling and on
linical outcomes in patients with decreased LVEF
nd heart failure and suggest that the placebo-
orrected effect of a drug or device on the process of
Figure 8. Correlation of an Intervention’s Effect on Remodeling
Quantitative relationship between drug/device effects on ejection f
and mortality in patients with heart failure and left ventricular dysfu
(A), EDV (B), or ESV (C) from an individual remodeling trial plotted
were classiﬁed as favorable if the upper limit of the 95% conﬁdenc
neutral if the conﬁdence interval crossed 1, and adverse if the lowe
relation between longer term therapeutic effect on mortality and sh
p 0.001), EDV (r  0.44, p  0.002), and ESV (r  0.48, p  0.002
trolled trials (RCTs) of 25 interventions, including 19,092 total patients.emodeling can serve as a probability signal of that
ntervention’s potential effect on mortality. Certainly,
n intervention might exert a favorable effect on
linical outcomes through mechanisms divorced from
hose responsible for LV remodeling. In the case of
ldosterone receptor blockade, we postulate that at
east some of the outcome benefit may be mediated
hrough vascular effects. Conversely, off-target adverse
ffects may offset the clinical benefit derived from a
rug’s or device’s favorable impact on the progression
f myocardial pathology. Nevertheless, results of our
eta-analysis support the use of remodeling data as a
eans of selecting agents to seek evidence of outcome
enefit through larger scale investigation, focusing on
linical events. Further, although remodeling benefit
annot be taken as a definitive surrogate end point for
urvival, demonstrable remodeling benefit of a drug or
evice serves to substantiate and render more credible
survival signal observed with that intervention.
onclusions
he process of ventricular remodeling is well estab-
ished and well described in animal models of LV
on Mortality
on (EF), end-diastolic volume (EDV), end-systolic volume (ESV),
ion. Each data point represents a placebo-corrected change in EF
nst the mortality odds ratio for the speciﬁc therapy. Interventions
erval of the odds ratio for death from the mortality trials was 1,
it of the conﬁdence interval was 1. There was a signiﬁcant cor-
term therapeutic effect on left ventricular EF (r  0.51,
modeling data derived from analysis of 86 randomized, con-and
racti
nct
agai
e int
r lim
ort-
). ReReprinted, with permission, from Kramer et al. (81).
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106tress and injury and in patients after MI and other
orms of dilated cardiomyopathy. Various tech-
iques have been developed to explore the remod-
ling process in patients, each carrying advantages
nd disadvantages. These techniques have been
xtensively deployed in clinical trials, demonstrating
he value of baseline LV volumes and change in LV
imension, area, and volume over time, for predict-
ng subsequent clinical outcomes. Beyond LV vol-
mes, the pattern of LV remodeling was recently
hown to carry additional predictive value for vas-
ular and heart failure-related events. These find-
ngs support the hypothesis that the linkage be-
ween LV remodeling and outcome occurs not
erely through the adverse impact of cardiac pa-sults of one-year serial echocardio-
graphic follow-up from the Captopril angiotensin convertogic change as a measure of concomitant vascular
athology. Finally, our recent meta-analysis corre-
ating drug and device effects on LV volumes and
n survival within a given population strengthens
ur understanding of the impact of remodeling
hanges on clinical outcomes in heart failure and
rovides support for the use of remodeling param-
ters to guide subsequent larger scale clinical inves-
igation and to help substantiate a given outcome
ignal within a given population.
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